keyword
https://read.qxmd.com/read/24140730/relationship-between-statin-type-and-responsiveness-to-clopidogrel-in-patients-treated-with-percutaneous-coronary-intervention-a-subgroup-analysis-of-the-cilon-t-trial
#21
RANDOMIZED CONTROLLED TRIAL
Jung-Won Suh, Myung-Jin Cha, Seung-Pyo Lee, In-Ho Chae, Jang-Ho Bae, Taek-Geun Kwon, Jang-Whan Bae, Myeong-Chan Cho, Seung-Woon Rha, Hyo-Soo Kim
AIM: To compare the responsiveness to clopidogrel in patients who were prescribed two different types of statins, atorvastatin vs. rosuvastatin, following percutaneous coronary intervention. METHODS: A total of 915 patients were randomized according to the antiplatelet therapy strategy in the CILON-T trial. In this subgroup analysis, we included patients who took atorvastatin(20 mg/day, n=295) or rosuvastatin(10 mg/day, n=261) during the entire study period and underwent measurement of the P2Y12 reaction unit(PRU) values at both discharge and six months...
2014: Journal of Atherosclerosis and Thrombosis
https://read.qxmd.com/read/23858814/simvastatin-lnduced-nocturnal-leg-pain-disappears-with-pravastatin-substitution
#22
JOURNAL ARTICLE
Natasa Stojaković, Rajko Igić
INTRODUCTION: Statins have similar side effects that do not always occur at the same rate among the various statins. We present a case of simvastatin-induced muscle toxicity that disappeared when pravastatin was substituted for the original drug. CASE OUTLINE: A 74-year-old male, a nonsmoker, complained of severe nocturnal leg cramps. The patient also complained that similar painful cramping occurred when he walked rapidly or jogged. Because some components of his lipid panel exceeded the'desirable' range, and as he had a history of myocardial infarction, his family physician prescribed simvastatin (40 mg/day)...
May 2013: Srpski Arhiv za Celokupno Lekarstvo
https://read.qxmd.com/read/23822632/an-integrated-in-vitro-model-for-simultaneous-assessment-of-drug-uptake-metabolism-and-efflux
#23
JOURNAL ARTICLE
Etienne P A Neve, Per Artursson, Magnus Ingelman-Sundberg, Maria Karlgren
The absorption, distribution, metabolism, and excretion (ADME) of drugs in vivo are to a large extent dependent on different transport and metabolism routes. Elucidation of this complex transport-metabolism interplay is a major challenge in drug development and at present no in vitro models suitable for this purpose are at hand. The aim of this study was to develop flexible, well-controlled, easy-to-use, integrated cell models, where drug transport and drug metabolism processes could be studied simultaneously...
August 5, 2013: Molecular Pharmaceutics
https://read.qxmd.com/read/23256625/evaluation-of-drug-interactions-of-gsk1292263-a-gpr119-agonist-with-statins-from-in-vitro-data-to-clinical-study-design
#24
JOURNAL ARTICLE
Joseph W Polli, Elizabeth Hussey, Mark Bush, Grant Generaux, Glenn Smith, David Collins, Susan McMullen, Nancy Turner, Derek J Nunez
1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2...
June 2013: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://read.qxmd.com/read/22775412/diabetes-mellitus-reduces-the-clearance-of-atorvastatin-lactone-results-of-a-population-pharmacokinetic-analysis-in-renal-transplant-recipients-and-in-vitro-studies-using-human-liver-microsomes
#25
JOURNAL ARTICLE
Miroslav Dostalek, Wai-Johnn Sam, Komal R Paryani, Joyce S Macwan, Reginald Y Gohh, Fatemeh Akhlaghi
BACKGROUND AND OBJECTIVE: Patients with diabetes mellitus might be at a higher risk of HMG-CoA reductase inhibitor (statin)-induced myotoxicity, possibly because of reduced clearance of the statin lactone. The present study was designed to investigate the effect of diabetes on the biotransformation of atorvastatin acid, both in vivo in nondiabetic and diabetic renal transplant recipients, and in vitro in human liver samples from nondiabetic and diabetic donors. SUBJECTS AND METHODS: A total of 312 plasma concentrations of atorvastatin acid and atorvastatin lactone, from 20 nondiabetic and 32 diabetic renal transplant recipients, were included in the analysis...
September 1, 2012: Clinical Pharmacokinetics
https://read.qxmd.com/read/22227917/influence-of-atorvastatin-on-the-pharmacodynamic-and-pharmacokinetic-activity-of-repaglinide-in-rats-and-rabbits
#26
JOURNAL ARTICLE
Makula Chandra Sekhar, P Jaya Chandra Reddy
Dyslipidemia is common in patients with type 2 diabetes. Statins are used as the first choice in treatment of diabetic dyslipidemia. Atorvastatin represents a first-line treatment option, alongside other hydroxyl methylglutaryl coenzyme A reductase inhibitors. Repaglinide is a short-acting, oral, insulin secretagogue that is used in the treatment of type 2 diabetes mellitus. Both the category of drugs undergo extensive metabolism with cytochrome enzyme system. This may lead to drug-drug interaction problems with altered repaglinide activity which is cautious...
May 2012: Molecular and Cellular Biochemistry
https://read.qxmd.com/read/21630612/concomitant-use-of-simvastatin-and-amiodarone-resulting-in-severe-rhabdomyolysis-a-case-report-and-review-of-the-literature
#27
REVIEW
A Marot, J Morelle, V A Chouinard, M Jadoul, M Lambert, N Demoulin
Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy. Predisposing factors include comorbidities and the concomitant use of cytochrome P-450 (CYP) 3A4 inhibitors. We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy. Physicians should be aware of the risk of this potentially severe drug interaction. The dose of simvastatin should be reduced (to 20 mg daily) when concomitant treatment with amiodarone is required, or preference should be given to pravastatin, rosuvastatin or fluvastatin, which are not metabolised by the CYP 3A4...
March 2011: Acta Clinica Belgica
https://read.qxmd.com/read/21264118/drug-drug-interaction-between-pravastatin-and-gemfibrozil-antihyperlipidemic-with-gliclazide-antidiabetic-in-rats
#28
JOURNAL ARTICLE
Cm Sultanpur, S Satyanarayana, Ns Reddy, Ke Kumar, S Kumar
Diabetes mellitus is a condition of increased blood glucose level in the body. Antihyperlipidemic drugs like statins and fibrates are widely used for prophylactic treatment in dyslipideamia and atherosclerosis. Diabetic dislipidemia exists with increased triglycerides, low HDL and high LDL levels. Hence, with oral hypoglycemic drugs, the addition of a lipid-lowering drug is necessary for controlling dislipidemia. In such a situation, there may be chances of drug-drug interactions between antidiabetic and antihyperlipidemic drugs...
April 2010: Journal of Young Pharmacists: JYP
https://read.qxmd.com/read/20586571/colchicine-poisoning-the-dark-side-of-an-ancient-drug
#29
REVIEW
Yaron Finkelstein, Steven E Aks, Janine R Hutson, David N Juurlink, Patricia Nguyen, Gal Dubnov-Raz, Uri Pollak, Gideon Koren, Yedidia Bentur
INTRODUCTION: Colchicine is used mainly for the treatment and prevention of gout and for familial Mediterranean fever (FMF). It has a narrow therapeutic index, with no clear-cut distinction between nontoxic, toxic, and lethal doses, causing substantial confusion among clinicians. Although colchicine poisoning is sometimes intentional, unintentional toxicity is common and often associated with a poor outcome. METHODS: We performed a systematic review by searching OVID MEDLINE between 1966 and January 2010...
June 2010: Clinical Toxicology
https://read.qxmd.com/read/20178046/drug-interactions-with-hmg-coa-reductase-inhibitors-statins-the-importance-of-cyp-enzymes-transporters-and-pharmacogenetics
#30
REVIEW
Pertti J Neuvonen
HMG-CoA reductase inhibitors (statins) can cause skeletal muscle toxicity; the risk of toxicity is elevated by drug interactions and pharmacogenetic factors that increase the concentration of statins in the plasma. Statins are substrates for several membrane transporters that may mediate drug interactions. Inhibitors of the organic anion transporting polypeptide 1B1 can decrease the hepatic uptake of many statins, as well as the therapeutic index of these agents. Potent inhibitors of cytochrome P450 (CYP)3A4 can significantly increase the plasma concentrations of the active forms of simvastatin, lovastatin and atorvastatin...
March 2010: Current Opinion in Investigational Drugs
https://read.qxmd.com/read/20095333/-comparison-on-long-term-effects-of-atorvastatin-or-pravastatin-combined-with-clopidogrel-for-patients-undergoing-coronary-stenting-a-randomized-controlled-trial
#31
RANDOMIZED CONTROLLED TRIAL
Ya-Ling Han, Zi-Long Zhang, Yi Li, Shou-Li Wang, Quan-Min Jing, Zu-Lu Wang, Dong-Mei Wang
OBJECTIVE: To evaluate the long-term therapeutic effects of atorvastatin via cytochrome P450 (CYP)3A4 pathway or a non-CYP 3A4 pathway statin, pravastatin, combined with clopidogrel for the patients undergoing coronary stenting. METHODS: Between February 2006 and March 2007, a total of 1275 patients undergoing successful coronary stenting were randomly assigned to receive atorvastatin 20 mg/d (n = 638) or pravastatin 20 mg/d (n = 637). All patients received standard clopidogrel therapy...
August 25, 2009: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://read.qxmd.com/read/19743887/a-proposal-for-a-pharmacokinetic-interaction-significance-classification-system-piscs-based-on-predicted-drug-exposure-changes-and-its-potential-application-to-alert-classifications-in-product-labelling
#32
JOURNAL ARTICLE
Akihiro Hisaka, Makiko Kusama, Yoshiyuki Ohno, Yuichi Sugiyama, Hiroshi Suzuki
BACKGROUND AND OBJECTIVE: Pharmacokinetic drug-drug interactions (DDIs) are one of the major causes of adverse events in pharmacotherapy, and systematic prediction of the clinical relevance of DDIs is an issue of significant clinical importance. In a previous study, total exposure changes of many substrate drugs of cytochrome P450 (CYP) 3A4 caused by coadministration of inhibitor drugs were successfully predicted by using in vivo information. In order to exploit these predictions in daily pharmacotherapy, the clinical significance of the pharmacokinetic changes needs to be carefully evaluated...
2009: Clinical Pharmacokinetics
https://read.qxmd.com/read/19544679/platelet-aggregation-inhibition-in-patients-receiving-statins-either-fully-or-partially-metabolized-by-cyp3a4
#33
RANDOMIZED CONTROLLED TRIAL
Sotir Polena, Manish P Gupta, Hafiza Shaikh, Kathleen Zazzali, Neil Coplan, Jonas Gintautas, Subir Singh Labana, Daniel Soffer
Clopidogrel therapy is the standard for prevention of cardiovascular thrombotic events. Clopidogrel is converted to an active thiol by the cytochrome P450 CYP 3A4 and 2C19 enzymes. Recent studies suggest that statins metabolized by CYP3A4 attenuate the anti-aggregatory effect of clopidogrel. We evaluated the effect of CYP3A4-metabolized statins (atorvastatin, group 1) and partially-CYP3A4-metabolized statins (simvastatin, group 2) on platelet aggregation inhibition (PAI) when given concomitantly with clopidogrel as compared to patients who were statin naive (group 3)...
2008: Proceedings of the Western Pharmacology Society
https://read.qxmd.com/read/19398603/effects-of-statins-on-the-pharmacokinetics-of-midazolam-in-healthy-volunteers
#34
RANDOMIZED CONTROLLED TRIAL
Makiko Kokudai, Naoki Inui, Kazuhiko Takeuchi, Toshiyuki Sakaeda, Yoshiyuki Kagawa, Hiroshi Watanabe
Lipid-lowering agents, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), are widely used to prevent coronary artery disease and often coadministered with other drugs, but there is a possibility that they induce pharmacological interactions with concomitant drugs. The authors aimed to investigate whether statins have any influence on cytochrome P450 (CYP) 3A4 enzyme activity. Eleven healthy volunteers were enrolled and evaluated for the effects of statins on the pharmacokinetics of midazolam in an open-label, randomized, 3-way crossover trial with simvastatin 10 mg, atorvastatin 10 mg, and pitavastatin 2 mg...
May 2009: Journal of Clinical Pharmacology
https://read.qxmd.com/read/19376416/severe-rhabdomyolysis-and-acute-renal-failure-secondary-to-concomitant-use-of-simvastatin-with-rapamycin-plus-tacrolimus-in-liver-transplant-patient
#35
JOURNAL ARTICLE
C Dopazo, I Bilbao, J L Lázaro, G Sapisochin, M Caralt, L Blanco, L Castells, R Charco
OBJECTIVE: To report a severe interaction between simvastatin and rapamycin resulting in rhabdomyolysis and acute renal failure in a liver transplant patient. BACKGROUND: A 56-year-old man with hepatitis C virus cirrhosis (Child B) was diagnosed with hepatocellular carcinoma and underwent liver transplantation in April 2007. He was immunosuppressed with tacrolimus (FK) and mycophenolate mofetil (MMF). Postoperative complications were arterial hypertension and renal insufficiency...
April 2009: Transplantation Proceedings
https://read.qxmd.com/read/18720283/contribution-of-cytochrome-p450-3a4-and-3a5-to-the-metabolism-of-atorvastatin
#36
JOURNAL ARTICLE
J-E Park, K-B Kim, S K Bae, B-S Moon, K-H Liu, J-G Shin
Atorvastatin is a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor that is mainly metabolized by cytochrome P450 (CYP) 3A4. A recent study showed that the lipid-lowering effect of statins is affected by the CYP3A5 polymorphism. Therefore, it was investigated whether CYP3A5 contributes to the metabolism of atorvastatin. Two metabolites of atorvastatin, para- and ortho-hydroxyatorvastatin, were produced by human liver microsomes and human recombinant CYP3A enzymes, and the enzyme kinetic pattern exhibited substrate inhibition...
September 2008: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://read.qxmd.com/read/18665658/secondary-prevention-of-coronary-heart-disease-in-elderly-patients-following-myocardial-infarction-are-all-hmg-coa-reductase-inhibitors-alike
#37
REVIEW
Bijesh P Maroo, Carl J Lavie, Richard V Milani
Cardiovascular disease remains the leading cause of mortality in elderly patients. While coronary heart disease (CHD) morbidity and mortality have decreased over the last 25 years, the percentage reduction in elderly patients is nearly 50% lower than that for the general adult population. Therefore, aggressive primary and secondary prevention of CHD is imperative for our society, and hyperlipidaemia remains the major modifiable risk factor in the elderly population. However, there appears to be a reluctance among practitioners to treat hyperlipidaemia in elderly patients, a bias that is particularly important given the absolute benefits of treating such patients...
2008: Drugs & Aging
https://read.qxmd.com/read/18558792/risk-management-of-simvastatin-or-atorvastatin-interactions-with-cyp3a4-inhibitors
#38
JOURNAL ARTICLE
Espen Molden, Eva Skovlund, Pia Braathen
BACKGROUND: Co-administration of cytochrome P450 (CYP) 3A4 inhibitors with simvastatin or atorvastatin is associated with increased risk of developing myopathy or rhabdomyolysis. OBJECTIVE: To detect co-prescriptions of CYP3A4 inhibitors with simvastatin or atorvastatin in community pharmacies and assess the risk-preventive actions taken by the prescribing physicians who were alerted about the co-prescription by the pharmacist. METHODS: This naturalistic study was performed during four separate 6-week periods in 2004 and 2005, and involved 110 Norwegian community pharmacists (25-30 in each period)...
2008: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://read.qxmd.com/read/18302447/frequency-and-clinical-relevance-of-drug-interactions-with-lovastatin-and-simvastatin-an-observational-database-study
#39
JOURNAL ARTICLE
Tuire Tirkkonen, Anna Ryynänen, Tero Vahlberg, Kerttu Irjala, Timo Klaukka, Risto Huupponen, Kari Laine
BACKGROUND: Concomitantly used cytochrome P450 (CYP) 3A4 inhibitors and inducers have been shown to alter the plasma concentrations of the HMG-CoA reductase inhibitors ('statins') lovastatin and simvastatin. Myopathy is a serious adverse effect of statins. Concurrent use of statins with fibrates in particular seems to increase the risk of this adverse effect. OBJECTIVE: To evaluate the incidence and clinical consequences of the use of lovastatin or simvastatin with concomitant CYP3A4 inhibitors and inducers, and with fibrates...
2008: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://read.qxmd.com/read/18040809/mdr-and-cyp3a4-mediated-drug-drug-interactions
#40
REVIEW
Dhananjay Pal, Ashim K Mitra
P-glycoprotein (P-gp), multiple drug resistance associated proteins (MRPs), and cytochrome P450 3A4 together constitute a highly efficient barrier for many orally absorbed drugs. Multidrug regimens and corresponding drug-drug interactions are known to cause many adverse drug reactions and treatment failures. Available literature, clinical reports, and in vitro studies from our laboratory indicate that many drugs are substrates for both P-gp and CYP3A4. Our primary hypothesis is that transport and metabolism of protease inhibitors (PIs) and NNRTIs will be altered when administered in combination with azole antifungals, macrolide, fluroquinolone antibiotics, statins, cardiovascular agents, immune modulators, and recreational drugs [benzodiazepines, cocaine, lysergic acid dithylamide (LSD), marijuana, amphetamine (Meth), 3,4-methylenedioxymethamphetamine (MDMA), and opiates] due to efflux, and/or metabolism at cellular targets...
September 2006: Journal of Neuroimmune Pharmacology: the Official Journal of the Society on NeuroImmune Pharmacology
keyword
keyword
73098
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.